NASDAQ: IPA - ImmunoPrecise Antibodies Ltd.

Rentabilidade por seis meses: -59%
Rendimento de dividendos: 0.00%
Setor: Healthcare

Cronograma de promoção ImmunoPrecise Antibodies Ltd.


Sobre a empresa ImmunoPrecise Antibodies Ltd.

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes. The company also offers syngeneic cell line for immunization and screening; and peptide production for subsequent antibody discovery campaign.

mais detalhes
In addition, it provides B cell select platform which allows for the interrogation of animal antibody repertoire; screening of the immune repertoire of rabbits and chickens and select the desired antibody directly from the B cells; single step hybridoma, a semi-solid media to grow mouse and rat hybridomas; and DeepDisplay, a combination of transgenic animal platform and custom IPA phage display antibody selection. The company also offers phage display, a custom immune libraries from multiple species; and CAR development, an adaptable antibody which allows the inclusion of functional data early in the screening funnel. Further, it provides silico developability, a profiling toolset for antibody lead candidates; and vitro analytical tools for the study of various critical quality attributes. Additionally, the company offers LucinaTech, an antibody humanization to identify essential framework and CDR residues; antibody affinity maturation for therapeutic and diagnostic application; and antibody chimerization for cloning and production of variable antibody domain. It also provides Eurofins preclinical services; hybrid service model, a service model designed to reduce time and risk with custom technologies and applications; and breadth and depth to accelerate assay development, screening cascades, drug candidate validation, and new biotherapeutic concepts. The company was incorporated in 1983 and is headquartered in Victoria, Canada.

IPO date 2017-01-03
ISIN CA45257F2008
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета cad
Сайт https://www.ipatherapeutics.com
Цена ао 0.5425
Alteração de preço por dia: -1.18% (0.4149)
Alteração de preço por semana: +2.47% (0.4001)
Alteração de preço por mês: +2.63% (0.3995)
Alteração de preço em 3 meses: -36.68% (0.6475)
Mudança de preço em seis meses: -59% (1)
Mudança de preço por ano: -76.02% (1.71)
Mudança de preço em 3 anos: -92.87% (5.75)
Mudança de preço em 5 anos: -12.77% (0.47)
Mudança de preço em 10 anos: 0% (0.41)
Mudança de preço desde o início do ano: +0.4902% (0.408)

Subestimação

Nome Significado Nota
P/S 1.96 7
P/BV 1.41 9
P/E 0 0
EV/EBITDA -2.54 0
Total: 5.25

Eficiência

Nome Significado Nota
ROA, % -39.44 0
ROE, % -59.26 0
Total: 0

Dividendos

Nome Significado Nota
Div yield, % 0 0
DSI 0 0
Total: 1.02

Obrigação

Nome Significado Nota
Debt/EBITDA -0.5961 10
Total: 9.6

Impulso de crescimento

Nome Significado Nota
Rentabilidade Revenue, % 74.41 8
Rentabilidade Ebitda, % 6165.75 10
Rentabilidade EPS, % 130.51 10
Total: 9.6

Instituições Volume Compartilhar, %
Ingalls & Snyder 1281305 4.87
Citadel Advisors Llc 75031 0.29
Northern Trust Corporation 60914 0.23
Squarepoint Ops LLC 47957 0.18
Bank of Montreal/Can/ 47521 0.18
Cibc World Markets, Inc. 41200 0.16
Gradient Capital Advisors, LLC 26808 0.1
Renaissance Technologies, LLC 23000 0.09
Millennium Management LLC 19011 0.07
Geode Capital Management, LLC 17484 0.07



Supervisor Cargo Pagamento Ano de nascimento
Dr. Jennifer Lynne Bath Ph.D. CEO, President & Non-Independent Director 1.02M
Dr. Ilse Roodink Chief Scientific Officer & Interim General Manager of IPA Europe, Oss 277.03k

Endereço: Canada, Victoria, 3204–4464 Markham Street - abrir no Google Maps, abrir mapas Yandex
Site: https://www.ipatherapeutics.com